肝门部胆管癌外科治疗预后影响因素分析*

doi:10.3969/j.issn.1672-5069.2018.04.012

摘要/Abstract

摘要： 目的探讨影响外科治疗肝门部胆管癌（HCCA）患者预后的因素。方法 2010年1月~2014年1月收治的HCCA患者120例,行手术切除者67例【其中行根治性切除30例,姑息性切除（R1,R2）37例】和行胆管引流术53例（内引流术30例,外引流术23例）。结果 120例HCCA患者术后1 a、2 a、3 a生存率分别为67.5%（81/120）、45.8%（55/120）、25.0%（30/120）,其中根治性切除患者1 a、2 a、3 a生存率分别为93.33%、73.33%、60.00%,生存时间为（30.26±5.26） m,显著高于姑息性切除患者的（67.57%、48.65%、32.43%)和（22.14±4.78） m或胆管引流术患者【（52.83%、28.30%、0.0%)和（15.21±3.74） m, P<0.05】,姑息性切除患者上述指标又显著高于胆管引流术患者（P<0.05）;COX多因素分析显示,手术方式、切缘情况、细胞分化程度、TNM分期、淋巴结转移和门静脉侵犯均为影响HCCA患者外科治疗后生存的独立危险因素（P<0.05）。结论影响HCCA患者治疗后预后的因素较多,应针对性地做出评估,给予合理的治疗,以使患者最大获益。

关键词: 肝门部胆管癌, 外科手术, 预后

Abstract: Objective To investigate the influencing factors of prognosis in patients with hilar cholangiocarcinoma（HCCA） after surgical treatment. Methods 120 patients with HCCA were recruited in our hospital between January 2010 and January 2014,and 67 patients received surgical resection,including 30 with radical resection and 37 with R1 or R2 palliative resection,and 53 received bile duct drainage. Results The 1-year,2-year and 3-year survival rates in the 120 patients with HCCA were 67.5% （81/120）,45.8% （55/120） and 25%（30/120）,respectively,after treatment,and the 1-year,2-year and 3-year survival rates in patients undergoing radical resection were 93.33%,73.33%,60.00%,and the survival time was（30.26±5.26） months,much higher than 67.57%,48.65%,32.43% or longer than（22.14±4.78） m in patients with palliative resection or 52.83%,28.30%,0.0% and （15.21±3.74） m in patients with bile duct drainage （P<0.05）;Cox multivariate analysis showed that the surgical method [Exp（β）=5.214],resection margin [Exp（β）=2.703],differentiation degree [Exp（β）=4.781],TNM stage [Exp（β）=6.987],lymph node metastasis [Exp（β）=2.751] and portal vein invasion [Exp（β）=3.254] were the independent risk factors for the prognosis of patients with HCCA after treatment（P<0.05）. Conclusion Precise surgery should be given in patients with HCCA with detailed analysis of influencing factors of prognosis, which might be evaluated before any approaches is taken.

Key words: Hilar cholangiocarcinoma, Surgery, Prognosis

刘连杰, 王石, 王烯冬, 武志雄. 肝门部胆管癌外科治疗预后影响因素分析^*[J]. 实用肝脏病杂志, 2018, 21(4): 533-536.

Liu Lianjie, Wang Shi, Wang Xidong, et al. Influencing factors of prognosis in patients with hilar cholangiocarcinoma after surgical treatment[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 533-536.

参考文献

[1] 朱倩,乔国梁,晏建军,等. 可切除肝门部胆管癌预后影响因素分析. 中华肝胆外科杂志,2014,20(9):662-666.
[2] Peng C,Li C,Wen T,et al.Left hepatectomy combined with hepatic artery resection for hilar cholangiocarcinoma:A retrospective cohort study.Int J Surg,2016,32:167-173.
[3] 刘振国,强永乾. 螺旋CT和MRI对肝内周围型胆管癌诊断价值分析. 实用肝脏病杂志,2016,19(5):591-594.
[4] 刘召波,卢实春,李宁,等. 肝门部胆管癌的外科治疗. 中华消化外科杂志,2013,12(3):186-190.
[5] Liska V,Treska V,Skalicky T,et al.Evaluation of tumor markers and their impact on prognosis in gallbladder,bile duct and cholangiocellular carcinomas-apilot study. Anticancer Res,2017
37(4):2003.
[6] Ebata T,Kosuge T,Hirano S,et al.Proposal to modify the international union against cancer staging system for perihilar cholangiocarcinomas. Br J Surg,2014,101(2):79.
[7] Tsai CY,Watanabe N,Ebata T,et al.Right hepatectomy for a detoured left hepatic artery in hilar cholangiocarcinoma-report of a rare but rational resection. World J Surg Oncol,2016,14(1):288-394.
[8] Moon A,Chin S,Kim H K,et al.EGFR,COX2,p-AKT expression and PIK3CA mutation in distal extrahepatic bile duct carcinoma. Pathology,2016,48(1):35.
[9] Lee SG,Song GW,Hwang S,et al.Surgical treatment of hilar cholangiocarcinoma in the new era:the Asan experience.J Hepatobiliary Pancreat Sci,2010,17(4):476-489.
[10] Noji T,Tsuchikawa T,Okamura K,et al.Concomitant hepatic artery resection for advanced perihilar cholangiocarcinoma:a case-control study with propensity score matching. J Hepatobiliary Pancreat Sci,2016,23(7):442-448.
[11] Xiong JJ,Nunes QM,Huang W,et al.Preoperative biliary drainage in patients with hilar cholangiocarcinoma undergoing major hepatectomy. World J Gastroenterol,2013,19(46):8731-8739.
[12] Machado MA,Makdissi FF,Surjan RC.Right trisectionectomy with principle en bloc portal vein resection for right-sided hilar cholangiocarcinoma:no-touch technique.Ann Surg Oncol,2012,19(4):1324-1325.
[13] 张辉,王孟龙. 单中心56例肝门部胆管癌的外科治疗. 中华肝胆外科杂志,2017,23(1):16-19.
[14] Kuriyama N,Isaji S,Tanemura A,et al.Transhepatic hilar approach for perihilar cholangiocarcinoma:significance of early judgment of resectability and safe vascular reconstruction.J Gastrointest Surg,2017,21(3):590-599.
[15] Seehofer D,Neuhaus P.Strategies to optimise roresection for hilar cholangiocarcinoma.Zentralbl Chir,2016,141(4):397-404.
[16] Oba A,Takahashi S,Kato Y,et al.Usefulness of resection for hepatocellular carcinoma with macroscopic bile duct tumor thrombus. Anticancer Res,2014,34(8):4367-4372.
[17] 曹光材,白江江,戴阿利. 胆管癌组织紧密连结蛋白18、丝氨酸蛋白酶抑制剂和p53蛋白表达及其临床意义. 实用肝脏病杂志,2017,20(3):312-315.
[18] Yeh TS,Wang F,Chen TC,et al.Expression profile of microRNA-200 family in hepatocellular carcinoma with bile duct tumor thrombus. Ann Surg,2014,259(2):346-354.
[19] Kasai Y,Hatano E,Seo S,et al.Hepatocellular carcinoma with bile duct tumor thrombus:surgical outcomes and the prognostic impact of concomitant major vascular invasion. World J Surg,2015,39(2):1485-1493.
[20] Yoshizawa T,Toyoki Y,Hirai H et al. Invasive micropapillary carcinoma of the extrahepatic bile duct and its malignant potential. Oncol Rep,2014,32(4):1355-1361.
[21] 殷晓煜,刘鑫,陈伟,等. 肝门部胆管癌手术切除的远期疗效及预后因素分析. 中华消化外科杂志,2016,15(4):329-333.
[22] 周少君,黄志勇. 肝内胆管癌根治性切除术后肿瘤复发转移的预后因素分析. 中国普通外科杂志,2014,23(8):1024-1029.
[23] 蔡文科,张永杰,卢军华,等. 术前血清CA19-9是肝门部胆管癌根治术患者预后的独立影响因素. 第二军医大学学报,2013,34(12):1333-1339.
[24] 金昌国,张利刚,欧阳才国,等. 49例肝门部胆管癌的手术治疗分析. 军事医学,2012,36(1):60-64.
[25] 余漪,周福平,郭玲玲,等. 术后肝功能指标对肝内胆管癌根治性切除患者预后的影响. 第二军医大学学报,2015,36(6):627-633.

肝门部胆管癌外科治疗预后影响因素分析^*

Influencing factors of prognosis in patients with hilar cholangiocarcinoma after surgical treatment

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱玉成, 闫家微, 孙景坤, 张秋月. 慢加急性肝衰竭患者血清二胺氧化酶水平及其临床意义探讨*[J]. 实用肝脏病杂志, 2019, 22(5): 672-675.
[2]	庄太平, 尹杨艳, 谢蔓芳, 冯乃超, 陈彩华. 人巨细胞病毒感染与肝炎综合征婴儿临床特点比较^*[J]. 实用肝脏病杂志, 2019, 22(4): 514-517.
[3]	彭思璐, 刘冰, 孙宏, 林剑, 潘志颖, 邓存良. HBV相关慢加急性肝衰竭患者预后及其影响因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 545-548.
[4]	戴青云, 王润东, 荚卫东. 术前预后营养指数评估肝细胞癌患者肝切除术后早期肿瘤复发价值探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 561-564.
[5]	高朋彬,赵晓彦,秦浩,吴凤影,钟海振,王琳,贾慧娜,李树娟. 戊型肝炎肝衰竭死亡原因分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 220-223.
[6]	王虎明,樊东升,徐杰,刘险峰,周宁,丽敏,包娜娜. 肝细胞癌患者癌组织miRNA-30c水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(2): 248-251.
[7]	张小舟,帅领,王庆大,杨楠. 接受TACE治疗的肝细胞癌患者血清miR-335水平变化及其对预后判断的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 268-271.
[8]	马德渊, 马元凤, 张殿隆, 李山林. HBV相关慢加急性肝衰竭患者血清角蛋白18水平及其与患者预后的关系探讨^*[J]. 实用肝脏病杂志, 2019, 22(1): 77-80.
[9]	马履翔, 张雪松. 超声引导下经皮射频消融治疗小肝癌患者疗效及预后分析^*[J]. 实用肝脏病杂志, 2019, 22(1): 125-128.
[10]	于旭彤, 蒋秀华, 祁婷婷, 何钦俊, 周福元, 陈永鹏, 文维群, 陈金军. 前瞻性研究四种出血事件评估标准评估慢加急性肝衰竭患者出血事件^*[J]. 实用肝脏病杂志, 2018, 21(6): 885-889.
[11]	安宝燕, 王云, 项晓刚, 陈利文, 闫蕾, 曹竹君, 丁叶舟, 汤伟亮, 林兰意, 谢青, 王晖. 乙型肝炎相关性肝细胞癌患者预后的多因素分析^*[J]. 实用肝脏病杂志, 2018, 21(6): 924-927.
[12]	李连海, 许惠玲, 王金榜. 肝脏CT三维重建评估肝门部胆管癌根治术临床应用研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 947-950.
[13]	孟令军, 张晓荣, 杨保金. 扩大的腹主动脉旁淋巴结清扫可改善Bismuth Ⅰ/II型肝门部胆管癌患者术后生存[J]. 实用肝脏病杂志, 2018, 21(5): 761-764.
[14]	黄建文, 杨友超, 徐长青, 文天夫. 根治性切除治疗原发性肝癌患者预后分析^*[J]. 实用肝脏病杂志, 2018, 21(4): 521-524.
[15]	王伟, 王惠芳, 翟景明, 封冰. 肝细胞癌患者血浆SPINK1水平及其与患者预后的关系分析[J]. 实用肝脏病杂志, 2018, 21(4): 525-528.